AllerGen investigator Dr. Bruce Mazer has been designated Interim Executive Director and Chief Scientific Officer (CSO) of the Research Institute of the McGill University Health Centre (RI-MUHC).
His appointment will be effective from October 1, 2016, until a new Executive Director/CSO is appointed.
Dr. Mazer has served in a Deputy role for this dual position, and also as Head of Child Health Research at the Montreal Children’s Hospital of the MUHC, since April 2015.
Within AllerGen, Dr. Mazer is leading a study to develop an effective and safe treatment of cow’s milk allergy with oral immunotherapy (OIT).
The RI-MUHC, which supports 460 researchers and over 1,200 graduate and post-doctoral students and fellows, is internationally recognized for its research in the biomedical sciences and health care.
Read the RI-MUHC press release.